Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Glecaprevir and Pibrentasvir in Renal Impairment
NCT02442258Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2015
- Primary completion
- Dec 2015
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label trial of glecaprevir and pibrentasvir in hepatitis C (HCV) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Area under the plasma concentration-time curve at 144 hours, Maximum plasma concentration at 144 hours and 1 more. Started Mar 2015; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02442258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442258.